文献
J-GLOBAL ID:201202210062578272
整理番号:12A1341367
BRAF変異結腸直腸癌の前臨床モデルにおけるBRAF阻害剤Vemurafenibの抗腫瘍活性
Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
著者 (13件):
YANG Hong
(Roche Pharmaceuticals, New Jersey)
,
HIGGINS Brian
(Roche Pharmaceuticals, New Jersey)
,
KOLINSKY Kenneth
(Roche Pharmaceuticals, New Jersey)
,
PACKMAN Kathryn
(Roche Pharmaceuticals, New Jersey)
,
BRADLEY William D.
(Roche Pharmaceuticals, New Jersey)
,
LEE Richard J.
(Roche Pharmaceuticals, New Jersey)
,
SCHOSTACK Kathleen
(Roche Pharmaceuticals, New Jersey)
,
SIMCOX Mary Ellen
(Roche Pharmaceuticals, New Jersey)
,
KOPETZ Scott
(MD Anderson Cancer Center, Texas)
,
HEIMBROOK David
(Roche Pharmaceuticals, New Jersey)
,
LESTINI Brian
(Roche Pharmaceuticals, New Jersey)
,
BOLLAG Gideon
(Plexxikon Inc., California)
,
SU Fei
(Roche Pharmaceuticals, New Jersey)
資料名:
Cancer Research
(Cancer Research)
巻:
72
号:
3
ページ:
779-789
発行年:
2012年02月01日
JST資料番号:
D0045B
ISSN:
0008-5472
CODEN:
CNREA8
資料種別:
逐次刊行物 (A)
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)